Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.)

Abstract Background Emamectin benzoate (EB) is a dominating pharmaceutical drug used for the treatment and control of infections by sea lice ( Lepeophtheirus salmonis ) on Atlantic salmon ( Salmo salar L). Fish with an initial mean weight of 132 g were experimentally medicated by a standard seven-da...

Full description

Bibliographic Details
Main Authors: Olsvik, Pål A, Lie, Kai K, Mykkeltvedt, Eva, Samuelsen, Ole B, Petersen, Kjell, Stavrum, Anne-Kristin, Lunestad, Bjørn T
Format: Article in Journal/Newspaper
Language:English
Published: BioMed Central Ltd. 2008
Subjects:
Online Access:http://www.biomedcentral.com/1471-2210/8/16
id ftbiomed:oai:biomedcentral.com:1471-2210-8-16
record_format openpolar
spelling ftbiomed:oai:biomedcentral.com:1471-2210-8-16 2023-05-15T15:30:24+02:00 Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.) Olsvik, Pål A Lie, Kai K Mykkeltvedt, Eva Samuelsen, Ole B Petersen, Kjell Stavrum, Anne-Kristin Lunestad, Bjørn T 2008-09-11 http://www.biomedcentral.com/1471-2210/8/16 en eng BioMed Central Ltd. http://www.biomedcentral.com/1471-2210/8/16 Copyright 2008 Olsvik et al; licensee BioMed Central Ltd. Research article 2008 ftbiomed 2008-09-26T23:12:13Z Abstract Background Emamectin benzoate (EB) is a dominating pharmaceutical drug used for the treatment and control of infections by sea lice ( Lepeophtheirus salmonis ) on Atlantic salmon ( Salmo salar L). Fish with an initial mean weight of 132 g were experimentally medicated by a standard seven-day EB treatment, and the concentrations of drug in liver, muscle and skin were examined. To investigate how EB affects Atlantic salmon transcription in liver, tissues were assessed by microarray and qPCR at 7, 14 and 35 days after the initiation of medication. Results The pharmacokinetic examination revealed highest EB concentrations in all three tissues at day 14, seven days after the end of the medication period. Only modest effects were seen on the transcriptional levels in liver, with small fold-change alterations in transcription throughout the experimental period. Gene set enrichment analysis (GSEA) indicated that EB treatment induced oxidative stress at day 7 and inflammation at day 14. The qPCR examinations showed that medication by EB significantly increased the transcription of both HSP70 and glutathione-S-transferase (GST) in liver during a period of 35 days, compared to un-treated fish, possibly via activation of enzymes involved in phase II conjugation of metabolism in the liver. Conclusion This study has shown that a standard seven-day EB treatment has only a modest effect on the transcription of genes in liver of Atlantic salmon. Based on GSEA, the medication seems to have produced a temporary oxidative stress response that might have affected protein stability and folding, followed by a secondary inflammatory response. Article in Journal/Newspaper Atlantic salmon Salmo salar BioMed Central
institution Open Polar
collection BioMed Central
op_collection_id ftbiomed
language English
description Abstract Background Emamectin benzoate (EB) is a dominating pharmaceutical drug used for the treatment and control of infections by sea lice ( Lepeophtheirus salmonis ) on Atlantic salmon ( Salmo salar L). Fish with an initial mean weight of 132 g were experimentally medicated by a standard seven-day EB treatment, and the concentrations of drug in liver, muscle and skin were examined. To investigate how EB affects Atlantic salmon transcription in liver, tissues were assessed by microarray and qPCR at 7, 14 and 35 days after the initiation of medication. Results The pharmacokinetic examination revealed highest EB concentrations in all three tissues at day 14, seven days after the end of the medication period. Only modest effects were seen on the transcriptional levels in liver, with small fold-change alterations in transcription throughout the experimental period. Gene set enrichment analysis (GSEA) indicated that EB treatment induced oxidative stress at day 7 and inflammation at day 14. The qPCR examinations showed that medication by EB significantly increased the transcription of both HSP70 and glutathione-S-transferase (GST) in liver during a period of 35 days, compared to un-treated fish, possibly via activation of enzymes involved in phase II conjugation of metabolism in the liver. Conclusion This study has shown that a standard seven-day EB treatment has only a modest effect on the transcription of genes in liver of Atlantic salmon. Based on GSEA, the medication seems to have produced a temporary oxidative stress response that might have affected protein stability and folding, followed by a secondary inflammatory response.
format Article in Journal/Newspaper
author Olsvik, Pål A
Lie, Kai K
Mykkeltvedt, Eva
Samuelsen, Ole B
Petersen, Kjell
Stavrum, Anne-Kristin
Lunestad, Bjørn T
spellingShingle Olsvik, Pål A
Lie, Kai K
Mykkeltvedt, Eva
Samuelsen, Ole B
Petersen, Kjell
Stavrum, Anne-Kristin
Lunestad, Bjørn T
Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.)
author_facet Olsvik, Pål A
Lie, Kai K
Mykkeltvedt, Eva
Samuelsen, Ole B
Petersen, Kjell
Stavrum, Anne-Kristin
Lunestad, Bjørn T
author_sort Olsvik, Pål A
title Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.)
title_short Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.)
title_full Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.)
title_fullStr Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.)
title_full_unstemmed Pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in Atlantic salmon (Salmo salarL.)
title_sort pharmacokinetics and transcriptional effects of the anti-salmon lice drug emamectin benzoate in atlantic salmon (salmo salarl.)
publisher BioMed Central Ltd.
publishDate 2008
url http://www.biomedcentral.com/1471-2210/8/16
genre Atlantic salmon
Salmo salar
genre_facet Atlantic salmon
Salmo salar
op_relation http://www.biomedcentral.com/1471-2210/8/16
op_rights Copyright 2008 Olsvik et al; licensee BioMed Central Ltd.
_version_ 1766360850819448832